Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fx-1006A (Tafamidis) in TTR Amyloid Cardiomyopathy
NCT00694161Phase 2Completed
- Sponsor
- Pfizer
- Start
- Aug 2008
- Primary completion
- Jan 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tafamidis in transthyretin amyloid cardiomyopathy (ATTR-CM), sponsored by Pfizer. Primary endpoint: Percentage of Participants With Stabilized Transthyretin (TTR Tetramer) at 6 weeks. Started Aug 2008; status: completed.
02
Drugs
tafamidis
03
Conditions
transthyretin amyloid cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on NCT00694161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00694161.